Skip to main content
. Author manuscript; available in PMC: 2021 Jun 10.
Published in final edited form as: Clin Immunol. 2019 Mar 26;202:49–58. doi: 10.1016/j.clim.2019.03.008

Fig. 2.

Fig. 2.

Alteration of ILC subset in SLE patients. PBMCs were collected from SLE patients and healthy controls. 49 SLE patients were scored and classified into inactive disease (SLEDAI: 0–4, n = 4) (data not shown), mild disease activity (SLEDAI: 5–9, n = 10), moderate disease activity (SLEDAI: 10–14, n = 16) and severe disease activity (SLEDAI > 15, n = 19), Percentages of ILC1/ILCs (A, D), ILC2/ILCs (B, E), ILC3/ILCs (C, F) in both groups are shown. Correlations between ILC1/ILCs (G), ILC2/ILCs (H), ILC3/ILCs (I) and SLEDAI are presented.